AU2020346818A1 - An immunotherapeutic for prostate cancer treatment - Google Patents

An immunotherapeutic for prostate cancer treatment Download PDF

Info

Publication number
AU2020346818A1
AU2020346818A1 AU2020346818A AU2020346818A AU2020346818A1 AU 2020346818 A1 AU2020346818 A1 AU 2020346818A1 AU 2020346818 A AU2020346818 A AU 2020346818A AU 2020346818 A AU2020346818 A AU 2020346818A AU 2020346818 A1 AU2020346818 A1 AU 2020346818A1
Authority
AU
Australia
Prior art keywords
gnrh
peptide
seq
oligomer
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020346818A
Other languages
English (en)
Inventor
Robert Bogden
Keith Douglas MILLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hexamer Therapeutics Inc
Original Assignee
Hexamer Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hexamer Therapeutics Inc filed Critical Hexamer Therapeutics Inc
Publication of AU2020346818A1 publication Critical patent/AU2020346818A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2020346818A 2019-09-12 2020-09-10 An immunotherapeutic for prostate cancer treatment Pending AU2020346818A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962899553P 2019-09-12 2019-09-12
US62/899,553 2019-09-12
PCT/US2020/050194 WO2021050722A1 (en) 2019-09-12 2020-09-10 An immunotherapeutic for prostate cancer treatment

Publications (1)

Publication Number Publication Date
AU2020346818A1 true AU2020346818A1 (en) 2022-03-03

Family

ID=74867215

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020346818A Pending AU2020346818A1 (en) 2019-09-12 2020-09-10 An immunotherapeutic for prostate cancer treatment

Country Status (10)

Country Link
US (1) US20220339238A1 (https=)
EP (2) EP4028043A4 (https=)
JP (2) JP7677953B2 (https=)
KR (1) KR20220062080A (https=)
CN (1) CN114599387A (https=)
AU (1) AU2020346818A1 (https=)
BR (1) BR112022004477A2 (https=)
CA (1) CA3152055A1 (https=)
MX (1) MX2022003100A (https=)
WO (1) WO2021050722A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7677953B2 (ja) * 2019-09-12 2025-05-15 ヘキサマー・セラピューティクス・インコーポレイテッド 前立腺癌処置のための免疫治療薬
US20230346920A1 (en) * 2020-05-04 2023-11-02 Hexamer Therapeutics, Inc. Vaccines against viral pathogens
CN118684781A (zh) * 2023-03-21 2024-09-24 深圳赫兹生命科学技术有限公司 GnRH-VLP重组去势疫苗及其制备方法
JP7837616B2 (ja) * 2025-07-25 2026-03-31 株式会社大都技研 遊技台

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723129A (en) * 1991-10-16 1998-03-03 University Of Saskatchewan GnRH-leukotoxin chimeras
WO1997015316A1 (en) * 1995-10-27 1997-05-01 Merck & Co., Inc. Conjugates of gonadotropin releasing hormone
US6319503B1 (en) * 1998-02-19 2001-11-20 Proteinix Company Heat shock fusion-based vaccine system
CU23204A1 (es) * 2002-12-27 2007-05-18 Ct Ingenieria Genetica Biotech Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias
CU23739A1 (es) * 2008-09-30 2011-12-28 Ct Ingenieria Genetica Biotech Composición farmacéutica utilizando combinaciones de variantes de la hormona liberadora de las gonadotropinas (gnrh) como inmunógeno
WO2015164798A1 (en) * 2014-04-25 2015-10-29 Tria Bioscience Corp. Synthetic hapten carrier compositions and methods
AU2016419048B2 (en) * 2016-08-11 2024-02-15 The Council Of The Queensland Institute Of Medical Research Immune-modulating compounds
MA52591A (fr) * 2018-07-12 2021-06-02 Hexamer Therapeutics Inc Échafaudage peptidique autoassemblé
JP7677953B2 (ja) * 2019-09-12 2025-05-15 ヘキサマー・セラピューティクス・インコーポレイテッド 前立腺癌処置のための免疫治療薬
US20230346920A1 (en) * 2020-05-04 2023-11-02 Hexamer Therapeutics, Inc. Vaccines against viral pathogens

Also Published As

Publication number Publication date
BR112022004477A2 (pt) 2022-05-31
JP2025124645A (ja) 2025-08-26
CN114599387A (zh) 2022-06-07
WO2021050722A1 (en) 2021-03-18
CA3152055A1 (en) 2021-03-18
EP4028043A1 (en) 2022-07-20
EP4028043A4 (en) 2023-08-02
EP4183417A1 (en) 2023-05-24
US20220339238A1 (en) 2022-10-27
MX2022003100A (es) 2022-04-06
JP7677953B2 (ja) 2025-05-15
JP2022548050A (ja) 2022-11-16
KR20220062080A (ko) 2022-05-13

Similar Documents

Publication Publication Date Title
EP4183417A1 (en) An immunotherapeutic for prostate cancer treatment
TWI379839B (en) Aβ immunogenic peptide carrier conjugates and methods of producing same
JP2023524054A (ja) ベータコロナウイルスの予防と治療
US20260061049A1 (en) Self-assembling peptide scaffold
CN113329762A (zh) 用于合成肽免疫原作为免疫刺激剂的人工混杂t辅助细胞表位
CN113574073A (zh) 针对降钙素基因相关肽(cgrp)的肽免疫原及其用于预防和治疗偏头痛的制剂
WO2020047107A1 (en) Synthetic carrier compositions for peptide vaccines
WO2023064631A1 (en) Engineering antigen binding to, and orientation on, adjuvants for enhanced humoral responses and immunofocusing
US20230346920A1 (en) Vaccines against viral pathogens
EP2987502B1 (en) Peptide adjuvants
EP4384534A1 (en) Truncated influenza neuraminidase and methods of using the same